CareDx, Inc.

CareDx, Inc. is a healthcare company that provides solutions for improving outcomes for transplant patients and advancing organ health. Its portfolio includes a range of diagnostic tests and monitoring tools for transplant recipients. For kidney transplant patients, it offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution, and HistoMap Kidney, which identifies allograft rejection in biopsy tissue. For heart transplant patients, it provides AlloMap Heart, a gene expression profiling solution, and AlloSure Heart, a dd-cfDNA solution. It also offers AlloSure Lung for lung transplant patients, HeartCare for monitoring distinct biological processes, and AlloHeme for predicting relapse in acute myeloid leukemia and myelodysplastic syndromes. Additionally, CareDx provides HLA typing solutions such as QTYPE and Olerup SSP, as well as AlloSeq Tx for high-resolution HLA typing, and transplant patient management software called Ottr.

CareDx, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol CDNA. The company is based in the United States and its stock is traded in US Dollars (USD). The exchange is a major US stock exchange, providing liquidity and visibility for the company's shares.

CareDx operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This industry focuses on developing diagnostic tests, monitoring tools, and research services that aid in the detection, management, and treatment of medical conditions. CareDx's products are primarily aimed at transplant patients, helping to monitor organ health and detect complications such as rejection or relapse.

CareDx provides its solutions for improving outcomes for transplant patients and advancing organ health in the United States and globally. While the company is headquartered in the United States, its products are available internationally. The company's portfolio includes tests and software that are used by transplant centers and healthcare providers worldwide to monitor transplant recipients and manage their care.

CareDx offers a comprehensive portfolio of transplant-related diagnostic and monitoring solutions. Notable products include AlloSure Kidney, a donor-derived cell-free DNA test for kidney transplant patients; AlloMap Heart, a gene expression profiling test for heart transplant patients; and AlloSure Heart and AlloSure Lung for heart and lung transplant monitoring, respectively. The company also provides HeartCare, which gives information about immune quiescence, active injury, and rejection types. For kidney biopsies, HistoMap Kidney identifies allograft rejection type. Additionally, AlloHeme monitors relapse in acute myeloid leukemia and myelodysplastic syndromes. In HLA typing, CareDx offers QTYPE, Olerup SSP, and AlloSeq Tx. The Ottr software helps manage transplant patients, and AlloSeq cfDNA and AlloSeq HCT provide surveillance and chimerism testing for stem cell transplant recipients.